Does atrial fibrillation detected by cardiac implantable electronic devices have clinical relevance?

Cardiology Clinics

Volumn 32, Issue 2, 2014, Pages 271-281

  Glotzer, Taya V ^a   Ziegler, Paul D ^b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Atrial fibrillation; Continuous monitoring; Implantable device; Stroke

Indexed keywords

ANTICOAGULATION; CARDIAC EQUIPMENT; CARDIAC IMPLANTED ELECTRONIC DEVICE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE DURATION; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART RHYTHM; HUMAN; IMPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUPRAVENTRICULAR TACHYCARDIA; THROMBOEMBOLISM; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); FORECASTING; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KAPLAN MEIER METHOD; MORTALITY; STROKE;

ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DEFIBRILLATORS, IMPLANTABLE; FORECASTING; HUMANS; KAPLAN-MEIER ESTIMATE; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

EID: 84899961268     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.11.001     Document Type: Review

References (38)

1. Page R.L., Wilkinson W.E., Clair W.K., et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994, 89:224-227.
2. Strickberger S.A., Ip J., Saksena S., et al. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2005, 2:125-131.
3. Quirino G., Giammaria M., Corbucci G., et al. Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol 2009, 32:91-98.
4. Orlov M.V., Ghali J.K., Araghi-Niknam M., et al. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the Atrial High Rate Trial. Pacing Clin Electrophysiol 2007, 30:404-411.
5. Israel C.W. Analysis of mode switching algorithms in dual chamber pacemakers. Pacing Clin Electrophysiol 2002, 25:380-393.
6. Passman R.S., Weinberg K.M., Freher M., et al. Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias. JCardiovasc Electrophysiol 2004, 15:773-777.
7. de Voogt W.G., van Hemel N.M., van de Bos A.A., et al. Verification of pacemaker automatic mode switching for the detection of atrial fibrillation and atrial tachycardia with Holter recording. Europace 2006, 8:950-961.
8. Pakarinen S., Toivonen L. Performance of atrial tachyarrhythmia-sensing algorithms in dual-chamber pacing using a fixed long AV delay in patients with sinus node dysfunction. JInterv Card Electrophysiol 2012, 35:207-213.
9. Kaufman E.S., Israel C.W., Nair G.M., ASSERT Steering Committee and Investigators, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012, 9:1241-1246.
10. Pollak W.M., Simmons J.D., Interian A., et al. Clinical utility of intra-atrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 2001, 24:424-429.
11. Purerfellner H., Gillis A.M., Holbrook R., et al. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004, 27:983-992.
12. Swerdlow C.D., Schoels W., Dijkman B., et al. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter-defibrillator. Circulation 2000, 101:878-885.
13. Ziegler P.D., Curwin J.H., Kremers M.S., et al. Accuracy of atrial fibrillation detection in implantable pacemakers. Heart Rhythm 2013, 10:S147.
14. Sarkar S., Ritscher D., Mehra R. Adetector for a chronic implantable atrial tachyarrhythmia monitor. IEEE Trans Biomed Eng 2008, 55:1219-1224.
15. Lian J., Wang L., Muessig D. Asimple method to detect atrial fibrillation using RR intervals. Am J Cardiol 2011, 107:1494-1497.
16. Hindricks G., Pokushalov E., Urban L., XPECT Trial Investigators, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010, 3:141-147.
17. Verma A., Champagne J., Sapp J., et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013, 173:149-156.
18. Glotzer T.V., Hellkamp A.S., Zimmerman J., et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics sub-study of MOST. Circulation 2003, 107:1614-1619.
19. Capucci A., Santini M., Padeletti L., Italian AT500 Registry Investigators, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. JAm Coll Cardiol 2005, 46:1913-1920.
20. Glotzer T.V., Daoud E.G., Wyse D.G., et al. Rationale and design of a prospective study of the clinical significance of atrial arrhythmias detected by implanted device diagnostics: TRENDS. JInterv Card Electrophysiol 2006, 15:9-14.
21. Fuster V., Ryden L.E., Asinger A.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 2001, 104:2118-2150.
22. Glotzer T.V., Daoud E.G., Wyse D.G., TRENDS Investigators, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009, 2:474-480.
23. Botto G.L., Padeletti L., Santini M., et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. JCardiovasc Electrophysiol 2009, 20:241-248.
24. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
25. Shanmugam N., Boerdlein A., Proff J., et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure- cardiac resynchronization therapy population. Europace 2012, 14:230-237.
26. Healey J.S., Connolly S.J., Gold M.R., ASSERT Investigators, et al. Subclinical atrial fibrillation and the risk of stroke. NEngl J Med 2012, 366:120-129.
27. Hohnloser S.H., Capucci A., Fain E., et al. ASymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT). Am Heart J 2006, 152:442-447.
28. Daoud E.G., Glotzer T.V., Wyse D.G., TRENDS Investigators, et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011, 8:1416-1423.
29. Hanke T., Charitos E.I., Stierle U., et al. Twenty-four-hour Holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy. Up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation 2009, 120(Suppl 11):S177-S184.
30. Ziegler P.D., Koehler J.L., Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006, 3:1445-1452.
31. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012, 110:1309-1314.
32. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a prior history of thromboembolic events. Stroke 2010, 41:256-260.
33. Ip J., Waldo A.L., Lip G.Y., et al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter- defibrillator and CRT-D devices: rationale, design, and clinical characteristics of the initially enrolled cohort. The IMPACT study. Am Heart J 2009, 158:364-370.
34. Reiffel J., Verma A., Halperin J.L., et al. Rationale and design of Reveal AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high risk patients. Am Heart J 2014, 167:22-27.
35. Prevalence of sub-clinical atrial fibrillation using an implantable cardiac monitor (ASSERT-II). Available at:. Accessed January 2, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01694394.
36. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
37. Glotzer T.V., Zeigler P.D. Silent AF as a stroke risk factor and anticoagulation indication. Can J Cardiol 2013, 29:S14-S23.
38. Healey J.S., Martin J.L., Duncan A., et al. Pacemaker-detectedatrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol 2013, 29:224-228.